Used as a potent inhibitor in targeted cancer therapies, particularly in the treatment of certain tyrosine kinase-driven tumors. It interferes with abnormal signaling pathways in cancer cells, especially those involving EGFR and HER2 mutations, helping to suppress tumor growth and proliferation. Its structure allows for high selectivity and improved pharmacokinetic properties, making it suitable for oral administration in chronic treatment regimens. Commonly investigated in non-small cell lung cancer and other solid tumors where resistance to earlier-generation inhibitors has developed. Shows activity against both wild-type and resistant mutant forms of kinase targets, contributing to its use in second-line therapeutic settings.